ABSTRACT
INTRODUCTION
Effective screening for preterm pre-eclampsia (PE) can be provided at 11-13 weeks' gestation by assessment of a combination of maternal characteristics and medical history (maternal factors) with multiples of the median (MoM) values of mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF) and pregnancy-associated plasma protein-A (PAPP-A). In a previous study, we used data from prospective screening in 35 948 singleton pregnancies at 11-13 weeks to develop an algorithm for the calculation of patient-specific risk of PE 1 . Bayes' theorem was used to combine the a-priori risk from maternal factors 2 with various combinations of MAP, UtA-PI, PAPP-A and PlGF 1 . In pregnancies with PE, the deviation from normal for each biomarker was inversely related to the gestational age at delivery and, consequently, the performance of screening was better for early than late PE. The performance of each biomarker in combination with maternal factors was superior to that of screening by maternal factors alone. Similarly, the performance of screening by a combination of two or more biomarkers was superior to that by individual biomarkers. The only exception was serum PAPP-A, which did not provide significant improvement to any combination of biomarkers that included serum PlGF. With combined screening by maternal factors, MAP, UtA-PI and PlGF, the detection rate (DR) of delivery with PE < 32, < 37 and ≥ 37 weeks was 89%, 75% and 47%, respectively, at a false-positive rate (FPR) of 10% 1 . A limitation of the study is that the performance of screening by a model derived and tested using the same dataset may be overestimated.
The objective of this study was to determine the accuracy of the previously reported first-trimester screening model for PE 1 in a prospective, non-intervention, multicenter study including 8775 singleton pregnancies. We hypothesize that the performance of screening would be similar to that estimated from the original model 1 .
METHODS

Study design and participants
This was a prospective, non-intervention, multicenter study in singleton pregnancies at 11 + 0 to 13 Eligibility criteria for study inclusion were maternal age ≥ 18 years, no serious mental illness or learning difficulty, singleton pregnancy with live fetus demonstrated on 11-13-week ultrasound scan and subsequent delivery of a phenotypically normal live birth or stillbirth ≥ 24 weeks' gestation. Multiple pregnancies, those with aneuploidy or major fetal abnormality and those ending in termination or miscarriage were excluded.
Test methods
The index test, or the test for which the accuracy was being evaluated, was the previously reported algorithm for first-trimester assessment of risk for PE by maternal factors and various combinations of MAP, UtA-PI, PAPP-A and PlGF 1 . Maternal factors were recorded 2 and MAP was measured by a validated automated device following a standardized protocol 4 . Transabdominal color Doppler ultrasound was performed to measure the left and right UtA-PI and the average value was recorded 5 . Serum PAPP-A and PlGF concentrations were measured using an automated device (PAPP-A and PlGF 1-2-3 TM kits, DELFIA ® Xpress random access platform; PerkinElmer Inc., Wallac Oy, Turku, Finland). All operators performing Doppler assessment had received the appropriate Certificate of Competence from The Fetal Medicine Foundation. Measured values of MAP, UtA-PI, PAPP-A and PlGF were expressed as MoM, adjusting for those characteristics found to provide a substantive contribution to the log 10 -transformed value, including maternal factors, in the prior model [6] [7] [8] [9] . The index test was carried out prospectively in consecutive singleton pregnancies at 11 + 0 to 13 + 6 weeks' gestation; gestational age was determined from the measurement of fetal crown-rump length 10 . The results from screening were not made available to the patients or their physicians.
The target condition was PE, as defined by the International Society for the Study of Hypertension in Pregnancy 11 . PE was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg on at least two occasions 4 hours apart, developing after 20 weeks of gestation in previously normotensive women. Hypertension was defined as proteinuria of ≥ 300 mg in 24 h or two readings of at least ++ on dipstick analysis of midstream or catheter urine specimens if no 24-h collection was available. PE superimposed on chronic hypertension was defined as significant proteinuria (as defined above) developing after 20 weeks of gestation in women with known chronic hypertension (history of hypertension before conception or presence of hypertension at booking visit before 20 weeks' gestation, in the absence of trophoblastic disease).
Data on pregnancy outcome were collected from the hospital maternity records of the women. The obstetric records of all women with pre-existing or pregnancyassociated hypertension were examined to determine if the condition was PE.
Statistical analysis
The previously described algorithm 1 was used for calculation of patient-specific risk of delivery with PE < 32, < 37 and ≥ 37 weeks' gestation. The prespecified analyses for performance of screening by maternal factors and any combinations of maternal factors with MAP, UtA-PI, PAPP-A and PlGF were estimation of areas under the receiver-operating characteristics curve (AUC) and DR, with 95% CI, at FPRs of 5% and 10%. The statistical software package R was used for data analyses 12 .
RESULTS
Participants
During the study period, 9041 pregnancies met the inclusion criteria and underwent screening for PE. A Table 2 Performance of screening for delivery with pre-eclampsia (PE) < 32, < 37 or ≥ 37 weeks' gestation in validation dataset of 8775 singleton pregnancies using previously developed algorithm based on maternal factors and combinations of biomarkers Values in parentheses are 95% CI. AUC, area under receiver-operating characteristics curve; DR, detection rate; FPR, false-positive rate; MAP, mean arterial pressure; PAPP-A, pregnancy-associated plasma protein-A; PlGF, placental growth factor; UtA-PI, uterine artery pulsatility index. total of 266 (2.9%) cases were excluded because they had a major fetal defect (n = 33), the pregnancy resulted in termination (n = 39) or miscarriage (n = 88) or there was no follow up (n = 106).
In the study population of 8775 pregnancies, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. Baseline demographic and clinical characteristics of the participants are shown in Table 1 . In total, 12 maternity hospitals in five different countries were involved in patient recruitment, 127 doctors participated in the measurement of UtA-PI and 152 doctors or nurses were involved in the measurement of MAP.
Test results
The AUC and DR, at FPRs of 5% and 10%, of delivery with PE < 32, < 37 and ≥ 37 weeks' gestation with screening by maternal factors and biomarkers using the previously reported algorithm 1 are given in Table 2 and compared to previously reported values in Figure 1 . The DRs in this validation dataset were similar to the estimated rates for the dataset used for development of the model.
The performance of screening for PE < 37 weeks was superior to that of PE ≥ 37 weeks. The best performance of screening was achieved by a combination of maternal factors, MAP, UtA-PI and PlGF and this was not improved significantly by addition of PAPP-A.
DISCUSSION
Main findings
This prospective multicenter validation study demonstrates the feasibility of incorporating first-trimester screening for PE into routine clinical practice. The findings demonstrate that the performance of screening for PE at 11-13 weeks by a combination of maternal factors and biomarkers is similar to that estimated from the original model 1 . The DR of screening by maternal factors, MAP, UtA-PI and PlGF, at 10% FPR, was 100% (95% CI, 80-100%) for PE < 32 weeks, 75% (95% CI, 62-85%) for PE < 37 weeks and 43% (95% CI, 35-50%) for PE ≥ 37 weeks; the estimated rates for the dataset used for development of the model were 89% (95% CI, 79-96%), 75% (95% CI, 70-80%) and 47% (95% CI, 44-51%), respectively 1 .
Study limitations
The main limitation of the study relates to the low incidence of delivery with PE, with the inevitable wide CIs obtained for performance of screening. Nevertheless, the values obtained in the validation study are similar to those in the dataset of 35 948 pregnancies used for development of the algorithm.
Implications for practice
Screening and diagnosis of PE is traditionally based on the demonstration of elevated blood pressure and proteinuria during a routine clinical visit in the late second or third trimester of pregnancy. In a proposed new pyramid of pregnancy care 13 , assessment of risk at 11-13 weeks' gestation aims to identify pregnancies at high risk of developing PE and, through pharmacological intervention with such medications as low-dose aspirin, to reduce the prevalence of these complications 14, 15 . The findings of this validation study confirm that screening at 11-13 weeks identifies a high proportion of cases that will develop PE < 37 weeks, but the performance of screening at this stage for those that will develop PE ≥ 37 weeks is poor 1 . This is particularly important because the prophylactic use of low-dose aspirin is effective in the prevention of preterm PE rather than term PE 16 . We reported previously that effective prediction of PE ≥ 37 weeks requires screening at 35-36 weeks 17 .
